
OSAKA -- A Japanese drugmaker plans clinical trials in the U.S. of a regenerative treatment for Parkinson's disease that uses reprogrammed cells, Nikkei has learned.
Sumitomo Dainippon Pharma aims for commercial breakthrough in iPS therapies
OSAKA -- A Japanese drugmaker plans clinical trials in the U.S. of a regenerative treatment for Parkinson's disease that uses reprogrammed cells, Nikkei has learned.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.